vs
Guardant Health, Inc.（GH）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是Rocket Lab Corp的1.6倍（$281.3M vs $179.7M），Rocket Lab Corp净利率更高（-29.5% vs -45.7%，领先16.2%），Guardant Health, Inc.同比增速更快（39.4% vs 35.7%），Guardant Health, Inc.自由现金流更多（$-54.2M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 29.2%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
GH vs RKLB — 直观对比
营收规模更大
GH
是对方的1.6倍
$179.7M
营收增速更快
GH
高出3.7%
35.7%
净利率更高
RKLB
高出16.2%
-45.7%
自由现金流更多
GH
多$60.0M
$-114.2M
两年增速更快
RKLB
近两年复合增速
29.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $179.7M |
| 净利润 | $-128.5M | $-52.9M |
| 毛利率 | 64.6% | 38.0% |
| 营业利润率 | -43.0% | -28.4% |
| 净利率 | -45.7% | -29.5% |
| 营收同比 | 39.4% | 35.7% |
| 净利润同比 | -15.8% | -1.1% |
| 每股收益（稀释后） | $-1.01 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRKLB
| Q4 25 | $281.3M | $179.7M | ||
| Q3 25 | $265.2M | $155.1M | ||
| Q2 25 | $232.1M | $144.5M | ||
| Q1 25 | $203.5M | $122.6M | ||
| Q4 24 | $201.8M | $132.4M | ||
| Q3 24 | $191.5M | $104.8M | ||
| Q2 24 | $177.2M | $106.3M | ||
| Q1 24 | $168.5M | $92.8M |
净利润GHRKLB
| Q4 25 | $-128.5M | $-52.9M | ||
| Q3 25 | $-92.7M | $-18.3M | ||
| Q2 25 | $-99.9M | $-66.4M | ||
| Q1 25 | $-95.2M | $-60.6M | ||
| Q4 24 | $-111.0M | $-52.3M | ||
| Q3 24 | $-107.8M | $-51.9M | ||
| Q2 24 | $-102.6M | $-41.6M | ||
| Q1 24 | $-115.0M | $-44.3M |
毛利率GHRKLB
| Q4 25 | 64.6% | 38.0% | ||
| Q3 25 | 64.7% | 37.0% | ||
| Q2 25 | 65.0% | 32.1% | ||
| Q1 25 | 63.3% | 28.8% | ||
| Q4 24 | 61.6% | 27.8% | ||
| Q3 24 | 61.1% | 26.7% | ||
| Q2 24 | 59.1% | 25.6% | ||
| Q1 24 | 61.2% | 26.1% |
营业利润率GHRKLB
| Q4 25 | -43.0% | -28.4% | ||
| Q3 25 | -37.3% | -38.0% | ||
| Q2 25 | -45.9% | -41.3% | ||
| Q1 25 | -54.6% | -48.3% | ||
| Q4 24 | -62.4% | -38.9% | ||
| Q3 24 | -61.3% | -49.5% | ||
| Q2 24 | -56.8% | -40.7% | ||
| Q1 24 | -59.2% | -46.4% |
净利率GHRKLB
| Q4 25 | -45.7% | -29.5% | ||
| Q3 25 | -35.0% | -11.8% | ||
| Q2 25 | -43.0% | -46.0% | ||
| Q1 25 | -46.8% | -49.5% | ||
| Q4 24 | -55.0% | -39.5% | ||
| Q3 24 | -56.3% | -49.6% | ||
| Q2 24 | -57.9% | -39.2% | ||
| Q1 24 | -68.2% | -47.7% |
每股收益（稀释后）GHRKLB
| Q4 25 | $-1.01 | $-0.09 | ||
| Q3 25 | $-0.74 | $-0.03 | ||
| Q2 25 | $-0.80 | $-0.13 | ||
| Q1 25 | $-0.77 | $-0.12 | ||
| Q4 24 | $-0.90 | $-0.11 | ||
| Q3 24 | $-0.88 | $-0.10 | ||
| Q2 24 | $-0.84 | $-0.08 | ||
| Q1 24 | $-0.94 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $1.0B |
| 总债务越低越好 | $1.5B | $152.4M |
| 股东权益账面价值 | $-99.3M | $1.7B |
| 总资产 | $2.0B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资GHRKLB
| Q4 25 | $378.2M | $1.0B | ||
| Q3 25 | $580.0M | $976.7M | ||
| Q2 25 | $629.1M | $688.1M | ||
| Q1 25 | $698.6M | $428.4M | ||
| Q4 24 | $525.5M | $419.0M | ||
| Q3 24 | $585.0M | $442.4M | ||
| Q2 24 | $933.7M | $496.8M | ||
| Q1 24 | $1.0B | $492.5M |
总债务GHRKLB
| Q4 25 | $1.5B | $152.4M | ||
| Q3 25 | $1.1B | $347.0M | ||
| Q2 25 | $1.1B | $346.5M | ||
| Q1 25 | $1.1B | $345.9M | ||
| Q4 24 | $1.1B | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益GHRKLB
| Q4 25 | $-99.3M | $1.7B | ||
| Q3 25 | $-354.5M | $1.3B | ||
| Q2 25 | $-305.5M | $688.5M | ||
| Q1 25 | $-250.8M | $431.3M | ||
| Q4 24 | $-139.6M | $382.5M | ||
| Q3 24 | $-60.1M | $419.8M | ||
| Q2 24 | $-1.6M | $455.2M | ||
| Q1 24 | $68.3M | $478.9M |
总资产GHRKLB
| Q4 25 | $2.0B | $2.3B | ||
| Q3 25 | $1.3B | $2.2B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.5B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
负债/权益比GHRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $-114.2M |
| 自由现金流率自由现金流/营收 | -19.3% | -63.6% |
| 资本支出强度资本支出/营收 | 9.9% | 27.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流GHRKLB
| Q4 25 | $-26.4M | $-64.5M | ||
| Q3 25 | $-35.4M | $-23.5M | ||
| Q2 25 | $-60.3M | $-23.2M | ||
| Q1 25 | $-62.7M | $-54.2M | ||
| Q4 24 | $-64.5M | $-2.4M | ||
| Q3 24 | $-51.1M | $-30.9M | ||
| Q2 24 | $-94.0M | $-13.0M | ||
| Q1 24 | $-30.3M | $-2.6M |
自由现金流GHRKLB
| Q4 25 | $-54.2M | $-114.2M | ||
| Q3 25 | $-45.8M | $-69.4M | ||
| Q2 25 | $-65.9M | $-55.3M | ||
| Q1 25 | $-67.1M | $-82.9M | ||
| Q4 24 | $-83.4M | $-23.9M | ||
| Q3 24 | $-55.3M | $-41.9M | ||
| Q2 24 | $-99.1M | $-28.3M | ||
| Q1 24 | $-37.2M | $-21.8M |
自由现金流率GHRKLB
| Q4 25 | -19.3% | -63.6% | ||
| Q3 25 | -17.3% | -44.8% | ||
| Q2 25 | -28.4% | -38.3% | ||
| Q1 25 | -33.0% | -67.6% | ||
| Q4 24 | -41.3% | -18.1% | ||
| Q3 24 | -28.9% | -40.0% | ||
| Q2 24 | -55.9% | -26.7% | ||
| Q1 24 | -22.1% | -23.5% |
资本支出强度GHRKLB
| Q4 25 | 9.9% | 27.6% | ||
| Q3 25 | 3.9% | 29.6% | ||
| Q2 25 | 2.4% | 22.2% | ||
| Q1 25 | 2.2% | 23.4% | ||
| Q4 24 | 9.4% | 16.3% | ||
| Q3 24 | 2.2% | 10.5% | ||
| Q2 24 | 2.9% | 14.4% | ||
| Q1 24 | 4.1% | 20.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
